NovaBridge Biosciences, a biotech company, focuses on the development of immuno-oncology agents for the treatment of cancer in the United States. The company is developing givastomig, a bispecific antibody, which is in Phase 1b clinical trial for the treatment of gastric cancer; uliledlimab, a CD73 neutralizing antibody; and ragistomig, a bispecific antibody, which is in phase 1 clinical trial for the treatment of solid tumors. It has a strategic licensing agreement with Ferring International Center SA to research, develop, make, have made, import, use, sell, and offer to sell FE301, an interleukin-6 inhibitor. The company also has collaborations with Bristol Myers Squibb for the development of givastomig; ABL Bio, Inc. for the development of givastomig and ragistomig; and TJ Bio for the development of uliledlimab. The company was formerly known as I-Mab and change its name to NovaBridge Biosciences in October 2025. NovaBridge Biosciences was founded in 2014 and is headquartered in Rockville, Maryland.
तुलना करने के लिए मीट्रिक्स | NBP | क्षेत्र सेक्टर - संबंधित क्षेत्र की कंपनियों के व्यापक समूह से मेट्रिक्स का औसत हेल्थकेयर | संबंध संबंधNBPपीअर्सक्षेत्र | |
|---|---|---|---|---|
पी/ई अनुपात | −3.5x | −11.6x | −0.5x | |
PEG अनुपात | 0.01 | −0.09 | 0.00 | |
क़ीमत/बुक | 1.3x | 7.9x | 2.6x | |
क़ीमत / एलटीएम बिक्री | - | 36.4x | 3.2x | |
अपसाइड (विश्लेषक लक्ष्य) | 214.8% | 172.2% | 44.2% | |
उचित मूल्य अपसाइड | अनलॉक करें | −1.9% | 5.5% | अनलॉक करें |